News25/Ratings4
News · 26 weeks450%
2025-12-142026-06-07
Mix2990d
- SEC Filings20(69%)
- Insider6(21%)
- Other3(10%)
Latest news
25 items- SECCingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Receives Complete Response Letter from FDA for CTx-1301No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter for its New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate HCl) for the treatment of A
- SECSEC Form DEF 14A filed by Cingulate Inc.DEF 14A - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form DEFA14A filed by Cingulate Inc.DEFA14A - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Leadership Update8-K - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form PRE 14A filed by Cingulate Inc.PRE 14A - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form 10-Q filed by Cingulate Inc.10-Q - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "Cingulate remains focused on disciplined execution in 2026 and we believe we are well positioned to bring our lead ADHD asset, CTx-1301, to market," said Cingulate CEO Shane J. Schaffer. "We continue to engage constructively with the FDA on our new drug application while advancing commercial readiness and manufacturing capabilities, and believe our
- INSIDERSEC Form 4 filed by EVP and CSO Silva Raul R.4 - Cingulate Inc. (0001862150) (Issuer)
- SECSEC Form 424B3 filed by Cingulate Inc.424B3 - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form EFFECT filed by Cingulate Inc.EFFECT - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form S-3 filed by Cingulate Inc.S-3 - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Leadership Update8-K - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form 424B3 filed by Cingulate Inc.424B3 - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form EFFECT filed by Cingulate Inc.EFFECT - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form EFFECT filed by Cingulate Inc.EFFECT - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders8-K - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form 424B3 filed by Cingulate Inc.424B3 - Cingulate Inc. (0001862150) (Filer)
- SECAmendment: SEC Form S-3/A filed by Cingulate Inc.S-3/A - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form DEFA14A filed by Cingulate Inc.DEFA14A - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form 10-K filed by Cingulate Inc.10-K - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsKANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i
- INSIDEREVP and CSO Silva Raul R. was granted 4,526 shares and covered exercise/tax liability with 1,828 shares, increasing direct ownership by 139% to 4,645 units (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
CING FAQ
6 questionsWhere does CING stock trade?
Cingulate Inc. (CING) is listed on NASDAQ.What sector and industry is CING in?
Cingulate Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cingulate Inc. go public?
Cingulate Inc. (CING) completed its IPO in 2021.What are analysts saying about CING?
Cingulate Inc. has had 4 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $1200.00 price target on 2025-01-10. Recent price targets range from $850.00 to $1200.00.What companies are similar to CING?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CING side-by-side with any of them on Quantisnow.How can I track CING on Quantisnow?
Quantisnow aggregates Cingulate Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CING to receive live email and push alerts on every new disclosure.